Article Data

  • Views 642
  • Dowloads 147

Original Research

Open Access

Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy

  • R. Du1
  • L. Li1,*,
  • S. Ma1
  • X. Tan1
  • S. Zhong1
  • M. Wu1

1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China

DOI: 10.12892/ejgo4754.2019 Vol.40,Issue 5,October 2019 pp.810-814

Accepted: 11 June 2018

Published: 10 October 2019

*Corresponding Author(s): L. Li E-mail: lileigh@163.com

Abstract

Objective: To determine risk factors of survival outcomes in patients with cervical cancer of Stage IB treated with standard hysterectomy (RH). Materials Methods: From February 2001 to November 2015, patients with cervical cancer of FIGO Stage IB were included, if they received RH of Class III or Type C1. Epidemiological and clinic-pathologic characteristics were compared to determine risk factors of overall survival (OS) and progression free survival (PFS). Results: Among 406 patients included, 371 (91.4%) had definite survival data, with recurrence rate and mortality of 17.2% and 9.4%. After a median follow-up of 48.5 (range 12-189) months, and ten-year PFS were 80% and 73%, and five- and ten-year OS were 88% and 84%, respectively. In multivariate analysis, patients with Stage IB2 (HR 2.0, 95% CI 1.2-3.2), positive vaginal margin (HR 9.2, 95% CI 2.6-33.0), or lymphatic metastasis (HR 2.0, 95% CI 1.1-3.6) had higher recurrence; patients with RH before year of 2011 (HR 2.8, 95% 1.3-6.0), Stage IB2 (HR 3.6, 95% CI 1.9-6.9) or lymphatic metastasis (HR 3.6, 95% CI 1.8-7.1) had higher mortality. Recurrent sites or post-recurrent treatment plans had no impact on the survival after recurrence. Conclusion: The prognosis of cervical cancer patients treated with RH by experienced physicians is favorable. Pathologic characters and experiences of surgeons are predictive factors of survival outcomes.

Keywords

Cervical cancer; Radical hysterectomy; Recurrence; Mortality

Cite and Share

R. Du,L. Li,S. Ma,X. Tan,S. Zhong,M. Wu. Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy. European Journal of Gynaecological Oncology. 2019. 40(5);810-814.

References

[1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[2] Chen W., Zheng R., Baade P.D., Zhang S., Zeng H., Bray F., et al.: “Cancer statistics in China, 2015”. CA Cancer J. Clin., 2016, 66, 115.

[3] Nezhat C.R., Burrell M.O., Nezhat F.R., Benigno B.B., Welander C.E.: “Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection”. Am. J. Obstet. Gynecol., 1992, 166, 864.

[4] Geetha P., Nair M.K.: “Laparoscopic, robotic and open method of radical hysterectomy for cervical cancer: A systematic review“. J. Minim. Access. Surg., 2012, 8, 67.

[5] Piver M.S., Rutledge F., Smith J.P.: “Five classes of extended hysterectomy for women with cervical cancer”. Obstet. Gynecol., 1974, 44, 265.

[6] Cibula D., Abu-Rustum N.R., Benedetti-Panici P., Kohler C., Raspagliesi F., Querleu D., et al.: “New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection”. Gynecol. Oncol., 2011, 122, 264.

[7] Querleu D., Morrow C.P.: “Classification of radical hysterectomy”. Lancet Oncol., 2008, 9, 297.

[8] “Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Available at: http://evs.nci.nih.gov/ftp1/CTCAE/

[9] Howlader N, Noone AM, Krapcho M, Neyman N., Aminou R., Waldron W., et al.: “SEER Cancer Statistics Review, 1975-2012”. National Cancer Institute. Bethesda, MD”. Available at: www.seer. cancer. gov

[10] Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J.: “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study”. Gynecol. Oncol., 1999, 73, 177.

[11] Ryu S.Y., Park S.I., Nam B.H., Cho C.K., Kim K., Kim B.J., et al.: “Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79, 794.

[12] atsuo K., Mabuchi S., Okazawa M., Kawano M., Kuroda H., Kamiura S., et al.: “Clinical implication of surgically treated earlystage cervical cancer with multiple high-risk factors”. J. Gynecol. Oncol., 2015, 26, 3.

[13] Peters W.A., 3rd, Liu P.Y., Barrett R.J., 2nd, Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[14] Fagundes H., Perez C.A., Grigsby P.W., Lockett M.A.: “Distant metastases after irradiation alone in carcinoma of the uterine cervix”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 24, 197.

[15] Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F.: “Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1990, 38, 352.

[16] Wright J.D., Lewin S.N., Deutsch I., Burke W.M., Sun X., Herzog T.J.: “The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer”. Am. J. Obstet. Gynecol., 2011, 205, 225.e221.

[17] Chou H.H., Wang C.C., Lai C.H., Hong J.H., Ng K.K., Chang T.C., et al.: “Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 51, 442.

[18] Jeon W., Koh H.K., Kim H.J., Wu H.G., Kim J.H., Chung H.H.: “Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer”. J. Gynecol. Oncol., 2012, 23, 168.

[19] Tempfer C.B., Beckmann M.W.: “State-of-the-Art Treatment and Novel Agents in Local and Distant Recurrences of Cervical Cancer”. Oncol. Res. Treat., 2016, 39, 525.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top